Premium
Influence of propranolol and 4‐hydroxypropranolol on platelet aggregation and thromboxane A 2 generation
Author(s) -
Mehta Jawahar,
Mehta Paulette,
Ostrowski Nancy
Publication year - 1983
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1983.215
Subject(s) - propranolol , platelet , chemistry , metabolite , pharmacology , thromboxane a2 , platelet aggregation , thromboxane , thromboxane b2 , biochemistry , endocrinology , medicine , biology
We examined in vitro effects of propranolol and its major metabolite, 4‐hydroxypropranolol, on human platelets. Both propranolol and its 4‐hydroxy metabolite had no significant direct effect on either platelet aggregation or TXA 2 generation in therapeutic concentrations. Higher concentrations (≥10 μg/ml), however, reduced both parameters of platelet function. When propranolol and 4‐hydroxypropranolol were incubated in combination with platelets in equal concentrations, there were synergistic effects on platelet aggregation and TXA 2 generation. Neither propranolol nor 4‐hydroxypropranolol inhibited platelet aggregation or TXA 2 synthesis in sonicated platelets at any concentration, indicating that intact platelet membrane is necessary for their action. Clinical Pharmacology and Therapeutics (1983) 34, 559–564; doi: 10.1038/clpt.1983.215